ArticleCancer immunology, immunotherapy : CII2025
Cathepsin S regulates antitumor immunity through autophagic degradation of PD-L1 in colorectal cancer cells.
Article in Cancer immunology, immunotherapy : CII, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Cathepsins as Core Players in Obesity Pathogenesis: Emerging Therapeutic Targets.Biomolecules · 2026Review
- Fluorescence-Guided Surgery in Colorectal Cancer: State-of-the-Art and Translational Perspectives.Current oncology (Toronto, Ont.) · 2026Review
- Mitochondria-targeted strategies in tumor immunity.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Colorectal cancer (CRC) is a major contributor to cancer-related mortality worldwide, highlighting the need to overcome its immunosuppressive tumor microenvironment. Cathepsin S (CTSS), a cysteine protease essential for MHC class II antigen presentation, has an unclear role in CRC immunity. This study investigated the impact of CTSS on PD-L1 expression and T-cell function in CRC. CTSS expression was analyzed in CRC tumor tissues and CTSS-deficient cell lines using immunohistochemistry, Western blotting, and flow cytometry. T-cell responses were assessed through granzyme B and IL-2 secretion assays, migration analysis, and gene set variation analysis (GSVA) of public datasets. Autophagy activity was evaluated via immunofluorescence, Western blotting, and lysosome isolation assays. An orthotopic CRC mouse model was used to study CTSS function in vivo. Key findings revealed that elevated CTSS expression correlated with higher PD-L1 levels in CRC tissues. CTSS suppression in CRC cells reduced PD-L1 expression while enhancing T-cell cytotoxicity and migration. GSVA further revealed an inverse correlation between CTSS expression and cytotoxic T-cell activity, alongside a strong association with autophagy-related pathways. Mechanistically, CTSS suppression in CRC cells promoted PD-L1 degradation by enhancing autophagic flux. In vivo, CTSS suppression inhibited tumor growth and enhanced CD8⁺ T-cell infiltration and activity. Anti-CD8 antibody treatment promoted tumor growth more significantly in CTSS-proficient CRC cells compared to CTSS-deficient cells. These findings demonstrate that CTSS regulates PD-L1 expression and T-cell cytotoxicity via autophagy-mediated pathways in CRC cells. Given ongoing development of CTSS inhibitors and autophagy modulators, targeting CTSS may offer a promising strategy to improve CRC immunotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.